Insys Therapeutics, Inc. (NASDAQ:INSY) major shareholder John N. Kapoor Trust Dated Sept bought 17,500 shares of the stock in a transaction dated Friday, August 11th. The stock was purchased at an average price of $8.93 per share, with a total value of $156,275.00. Following the acquisition, the insider now directly owns 31,982 shares in the company, valued at approximately $285,599.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Insys Therapeutics, Inc. (NASDAQ INSY) traded up 2.58% during midday trading on Monday, hitting $9.14. 438,214 shares of the stock traded hands. The stock has a 50-day moving average of $11.86 and a 200 day moving average of $11.42. The firm’s market cap is $664.44 million. Insys Therapeutics, Inc. has a 52-week low of $8.70 and a 52-week high of $18.80.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The firm had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. During the same quarter in the prior year, the firm posted $0.13 earnings per share. Insys Therapeutics’s quarterly revenue was down 38.4% on a year-over-year basis. Equities analysts forecast that Insys Therapeutics, Inc. will post ($0.29) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Insys Therapeutics, Inc. (NASDAQ:INSY) Major Shareholder Purchases $156,275.00 in Stock” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/14/insys-therapeutics-inc-nasdaqinsy-major-shareholder-purchases-156275-00-in-stock.html.

Large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in shares of Insys Therapeutics by 0.5% in the second quarter. Wells Fargo & Company MN now owns 27,667 shares of the specialty pharmaceutical company’s stock worth $350,000 after buying an additional 126 shares in the last quarter. Eqis Capital Management Inc. raised its stake in shares of Insys Therapeutics by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 66,121 shares of the specialty pharmaceutical company’s stock worth $836,000 after buying an additional 404 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Insys Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 79,943 shares of the specialty pharmaceutical company’s stock worth $1,012,000 after buying an additional 475 shares in the last quarter. American International Group Inc. raised its stake in shares of Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 953 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. raised its stake in shares of Insys Therapeutics by 4.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 37,885 shares of the specialty pharmaceutical company’s stock worth $479,000 after buying an additional 1,541 shares in the last quarter. 27.85% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently issued reports on INSY. Royal Bank Of Canada set a $16.00 target price on shares of Insys Therapeutics and gave the stock a “buy” rating in a report on Saturday, June 3rd. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “strong-buy” rating and set a $15.00 target price for the company in a report on Wednesday, July 12th. BidaskClub upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 8th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Insys Therapeutics in a report on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Insys Therapeutics and gave the stock a “hold” rating in a report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $13.25.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.